GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Echo Therapeutics Inc (OTCPK:ECTE) » Definitions » EPS without NRI

Echo Therapeutics (Echo Therapeutics) EPS without NRI : $-1.28 (TTM As of Sep. 2016)


View and export this data going back to 1997. Start your Free Trial

What is Echo Therapeutics EPS without NRI?

Echo Therapeutics's earnings per share without non-recurring items for the three months ended in Sep. 2016 was $-0.11. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2016 was $-1.28.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Echo Therapeutics's EPS without NRI or its related term are showing as below:

ECTE's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.8
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Echo Therapeutics's EPS (Diluted) for the three months ended in Sep. 2016 was $-0.11. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2016 was $-1.28.

Echo Therapeutics's EPS (Basic) for the three months ended in Sep. 2016 was $0.07. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2016 was $-1.10.


Echo Therapeutics EPS without NRI Historical Data

The historical data trend for Echo Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Echo Therapeutics EPS without NRI Chart

Echo Therapeutics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.89 -3.12 -2.33 -1.24 -1.98

Echo Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.12 -0.23 -0.82 -0.11

Competitive Comparison of Echo Therapeutics's EPS without NRI

For the Medical Devices subindustry, Echo Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Echo Therapeutics's PE Ratio without NRI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Echo Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Echo Therapeutics's PE Ratio without NRI falls into.



Echo Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Echo Therapeutics  (OTCPK:ECTE) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Echo Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Echo Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Echo Therapeutics (Echo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
99 Wood Avenue South, Suite 302, Iselin, NJ, USA, 08830
Echo Therapeutics Inc is a medical device company with expertise in skin permeation technology. It develops non-invasive, wireless continuous glucose monitoring system with potential use in the wearable health consumer and the diabetes outpatient market.
Executives
Michael M Goldberg director C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Uri Landesman 10 percent owner 230 PARK AVENUE, NEW YORK NY 10169
Platinum Partners Value Arbitrage Fund, Lp 10 percent owner 250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019
Mark Nordlicht 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Platinum Management (ny) Llc 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Platinum-montaur Life Sciences, Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Partners Liquid Opportunity Master Fund L.p. 10 percent owner 152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Liquid Opportunity Management (ny) Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD, MALVERN PA 19355
Vincent D Enright director ONE CORPORATE CENTER, RYE NY 10580
William Grieco director 830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Robert F Doman director, officer: EXEC. CHAIRMAN AND INTERIM CEO C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887
Patrick T Mooney director, officer: CEO AND PRESIDENT C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Christopher P. Schnittker officer: CFO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540

Echo Therapeutics (Echo Therapeutics) Headlines

No Headlines